|Bid||0.0100 x 0|
|Ask||0.0100 x 0|
|Day's range||0.0090 - 0.0100|
|52-week range||0.0037 - 0.0120|
|Beta (5Y monthly)||1.99|
|PE ratio (TTM)||N/A|
|Earnings date||01 Mar 2016 - 05 Mar 2016|
|Forward dividend & yield||N/A (N/A)|
|1y target est||0.25|
MELBOURNE, Australia, Jan. 13, 2020 -- Genetic Technologies (ASX: GTG; NASDAQ: GENE), a leader in the development of genetic risk assessment tests, recently announced the.
Molecular diagnostics company Genetic Technologies Limited (ASX: GTG, NASDAQ: GENE) is pleased to advise that its third-generation breast cancer test (GeneType for Breast Cancer) is on track for commercial release in the Unites States (US) in Q1 2020. Genetic Technologies expects to take advantage of the growing confidence and interest in genomic testing, and its first to market status in the US market. GeneType for breast cancer (BC) is on track for release in the US in Q1 (2020) via a soft launch across 20 centres in 8 States, which demonstrates the strong support from practitioners for the introduction of the company’s third generation test incorporating mammography data.
We often see insiders buying up shares in companies that perform well over the long term. The flip side of that is...
MELBOURNE, Australia, Dec. 17, 2019 -- Genetic Technologies Limited (ASX: GTG; Nasdaq: GENE, “Company”) is pleased to announce its interim-CEO, Dr. Jerzy Muchnicki, will share.
Genetic Technologies Limited (ASX: GTG; Nasdaq: GENE, “Company”) is pleased to announce the full commissioning of its Australian Laboratory for the provisioning of its generation 3 breast cancer test with sales to commence in Q1, 2020. Genetype for Breast Cancer is the world first Genomic test to accurately predict risk of disease by combining the information contained in your DNA with family history and mammography data to create a powerful new tool in the battle with breast cancer. Unlike BRCA gene testing which is used to detect the 1 in 400 women who carry this cancer associated genetic mutation, Genetype for Breast Cancer is relevant for the better management of 95% of all Breast cancers which are referred to as sporadic (or non-familial) and is ideally suited to be the first line test in a preventative medical genomic based health system.
MELBOURNE, Australia, Nov. 15, 2019 -- Genetic Technologies Limited (ASX: GTG; Nasdaq: GENE, “Company”), a diversified molecular diagnostics company, announced today an.
Genetic Technologies Limited (ASX: GTG; Nasdaq: GENE, “Company”), a diversified molecular diagnostics company, announced today an update to shareholders on recent achievements and upcoming milestones. As a result of the successful $4.5 million capital raise from existing shareholders, together with participation from domestic institutional and family office investors, the Company is now in compliance with Nasdaq listing requirements. The funds raised also position the Company to commence sales of its latest breast cancer and colorectal cancer risk assessment tests in both the U.S. and Australia.
Nasdaq: GENE, “Company”), a diversified molecular diagnostics company, today announced that it has entered into a securities purchase agreement with certain accredited institutional investors, pursuant to which the investors have agreed to purchase an aggregate of 1,476,143 American Depositary Shares (“ADSs”), each representing one hundred and fifty (150) of the Company’s ordinary shares, at a price of $0.80 per ADS. The Company will receive gross proceeds of approximately USD 1.2 million, before deducting customary offering expenses. The investors also agreed to purchase warrants to purchase an aggregate of 1,107,107 ADSs at an exercise price of $0.80 per share (the “Warrants”). The warrants will be exercisable immediately following the date of issuance, will expire on the five year anniversary of the date of issuance.
NASDAQ Ticker: GENE) is delighted to announce that following substantial scientific research and genetic product development, two new ground-breaking cancer risk assessment tests have now been completed and validated. The new tests for colorectal cancer and breast cancer are world-leading. GTG’s polygenic risk tests combine information from genetic markers called Single Nucleotide Polymorphisms to assess how people’s genetic make-up affects their risk of developing various diseases.
MELBOURNE, Australia, May 03, 2019 -- Molecular diagnostics company Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE) announces that it has received a letter from the.
Genetic Technologies Limited (ASX:GTG) (GENE) (“Company”), a provider of world-leading genetic risk assessment test products, is pleased to announce that it has now established a Memorandum of Understanding (MoU) with The Translational Genomics Research Institute (TGen). TGen is an Arizona-based, non-profit biomedical research institute dedicated to conducting ground-breaking research with life-changing results. TGen works to unravel the genetic components of common and complex diseases, including cancer, neurological disorders, infectious disease, and rare childhood disorders.
Highlights Genetic Technologies establishes Asian operations in China.The move into Asia includes the formation of Genetic Technologies HK Limited and Hainan Aocheng Genetic.
MELBOURNE, Australia, Feb. 01, 2019 -- Genetic Technologies Limited (ASX: GTG; Nasdaq: GENE, “Company”), a diversified molecular diagnostics company is pleased to announce the.